Pier 88 Investment Partners LLC Buys 7,910 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Pier 88 Investment Partners LLC increased its stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 7.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,610 shares of the company’s stock after buying an additional 7,910 shares during the period. Pier 88 Investment Partners LLC owned 0.20% of Pyxis Oncology worth $446,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fullcircle Wealth LLC purchased a new stake in Pyxis Oncology in the second quarter worth $40,000. SG Americas Securities LLC purchased a new stake in Pyxis Oncology in the first quarter worth about $59,000. The Manufacturers Life Insurance Company bought a new position in shares of Pyxis Oncology during the second quarter valued at approximately $65,000. Cetera Advisors LLC purchased a new position in shares of Pyxis Oncology during the first quarter valued at approximately $100,000. Finally, Schulhoff & Co. Inc. boosted its position in shares of Pyxis Oncology by 90.9% in the 2nd quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after purchasing an additional 20,000 shares in the last quarter. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research report on Friday, August 16th. Stephens initiated coverage on Pyxis Oncology in a report on Friday, November 8th. They set an “overweight” rating and a $13.00 price target on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research report on Thursday, September 19th. Finally, Stifel Nicolaus started coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 price target for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $9.57.

Pyxis Oncology Stock Down 7.4 %

PYXS stock opened at $4.28 on Thursday. The business’s 50-day moving average price is $3.65 and its 200-day moving average price is $3.65. Pyxis Oncology, Inc. has a twelve month low of $1.35 and a twelve month high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. On average, analysts expect that Pyxis Oncology, Inc. will post -1.04 EPS for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.